PhI/II Study ofREGN5668 Administered inCombw/Cemiplimab orREGN4018
Jill Tseng
- OPEN TO ACCRUAL
trials found matching your search:
Displaying 20 of 292 Results
NKX019 in Subjects with Myasthenia Gravis
Ali Habib
- OPEN TO ACCRUAL
A Phase 1 Study of NKX019 in Subjects with Immune-Mediated Disease
Tahseen Mozaffar
- OPEN TO ACCRUAL
A prospective, multicenter, single arm, open-label, feasibility study to evaluate the safety
Pengbo Jiang
- OPEN TO ACCRUAL
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topic
Maria Buethe
- OPEN TO ACCRUAL
SIENNA
Baruch Kuppermann
- OPEN TO ACCRUAL
GenePHIT: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Cl
Felice Lin
- OPEN TO ACCRUAL
A study to evaluate the efficacy and safety of frexalimab, SAR442970, or rilzabrutinib in participa
Ramy Hanna
- OPEN TO ACCRUAL
M6-C vs. ACDF 2-Level IDE Study
Yu-Po Lee
- OPEN TO ACCRUAL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Sanaz Attaripour Isfahani
- OPEN TO ACCRUAL
Lung Cancer Screening of Family Members of Patients with Mutation-Driven Lung Cancer
Hari Keshava
- OPEN TO ACCRUAL
An open-label study to assess safety, efficacy, and cellular kinetics of YTB323 in treatment-resista
Ali Habib
- OPEN TO ACCRUAL
SingleArmPhIV EvalSafe&EfficOral Fruquintinib Tx RefracMetsColoRecCa Pa UnderrepresentedMinorityPop
Farshid Dayyani
- OPEN TO ACCRUAL
PhIICemiplimabW/ChemoVsCemiplimabW/Chemo+OthCaTxPtsW/ResectNonSmalCelLungCa
Misako Nagasaka
- OPEN TO ACCRUAL
PhII Adj w/Pembrolizumab After Resec of Recur/2nd Primary H&N SCC W/High Risk Features
Shirin Attarian
- OPEN TO ACCRUAL
PREcisionDxProstateCaTx
Arash Rezazadeh Kalebasty
- OPEN TO ACCRUAL
A randomized placebo-controlled study to evaluate the efficacy and safety of dapirolizumab pegol in
Sheetal Desai
- OPEN TO ACCRUAL
A Prospective, Multicenter Study of the IndigoTM Aspiration System Seeking
Nadine Abi-Jaoudeh
- OPEN TO ACCRUAL
ShortTeRmIntensPembro&TivozanibHighRisRenalCellCa
Nataliya Mar
- OPEN TO ACCRUAL
RandomPhIIIBRAFTargetThe vsCabozantinibRAIRefractoryDifferentThyroidCa w/BRAFV600Em
Shirin Attarian
- OPEN TO ACCRUAL